ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Chinese Research Group Lands Financing

November 5, 2007 | APPEARED IN VOLUME 85, ISSUE 45

ShangPharma, a Shanghai-based contract research organization (CRO) whose subsidiary, Shanghai ChemExplorer, has a major contract with Eli Lilly & Co., has received a $30 million investment from the investor group TPG. ShangPharma, which claims to be China's leading CRO, says it plans to expand in the areas of assay development, compound screening, and drug metabolism and pharmacokinetic studies. It also plans to establish a current Good Manufacturing Practices-certified manufacturing facility.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment